Racial, ethnic, and socioeconomic disparities in rates of stage IV prostate cancer after USPSTF category "D" recommendation against prostate-specific antigen screening: a retrospective cohort study

被引:0
|
作者
Thakker, Parth U. [1 ]
Perry, Alan G. [2 ]
Hemal, Ashok K. [1 ]
Bercu, Caleb H. [1 ,2 ]
Petrou, Steven P. [2 ]
Pak, Raymond W. [2 ]
Broderick, Gregory A. [2 ]
Thiel, David D. [2 ]
Dora, Chandler D. [2 ]
Lyon, Timothy D. [2 ]
Igel, Todd C. [2 ]
Craven, Timothy E. [2 ]
Pathak, Ram A. [2 ]
机构
[1] Atrium Wake Forest Baptist Hlth, Dept Urol, Winston Salem, NC USA
[2] Mayo Clin, Dept Urol, 4500 San Pablo Rd S, Jacksonville, FL 32224 USA
关键词
African American; blood screening; Hispanics; prostate cancer (PCa); urology1103; MEN;
D O I
10.21037/tau-24-90
中图分类号
R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
摘要
Background: In 2012 the United States Preventative Services Task Force (USPSTF) changed its prostate-specific antigen (PSA) screening recommendation to a category "D". The purpose of this study is to examine racial, ethnic, and socioeconomic differences in risk of presentation with metastatic prostate cancer (mPCa) at time of diagnosis before and after the 2012 USPSTF category "D" recommendation. Methods: This is a population-based cohort study. We identified patients with mPCa at diagnosis within the National Cancer Database from 2004-2017. Logistic regression models were used to examine associations of mPCa with age, race, ethnicity, geographic location, education level, income, and insurance status. Linear regression models assuming underlying binomial distribution were fitted to annual percentage of mPCa at diagnosis for years 2012-2017 to evaluate the post category "D" recommendation era. Results: From 2004 to 2017, 88,987 patients presented with mPCa. A higher percentage of mPCa was noted post-USPSTF category "D" recommendation, with a disproportionately greater increase observed among Hispanics and non-Hispanic Blacks [Delta slope/year: Hispanics (0.0092), non-Hispanic Blacks (0.0073) and non-Hispanic Whites (0.0070)]. Insurance status impacts race/ethnicity differently: uninsured Hispanics were 3.66 times more likely to present with mPCa than insured Hispanics, while uninsured non-Hispanic Blacks were 2.62 times more likely to present with mPCa than insured non-Hispanic Blacks. Household income appears to be associated with differences in mPCa, particularly among non-Hispanic Blacks. Those earning <$30,000 were more likely to present with mPCa compared to higher income brackets. Conclusions: Since the USPSTF grade "D" recommendation against PSA screening, the percentage of mPCa at diagnosis has increased, with a higher rate of increase among Hispanic and non-Hispanic Blacks compared to non-Hispanic Whites.
引用
收藏
页码:1092 / 1103
页数:12
相关论文
共 50 条
  • [31] PROSTATE-SPECIFIC MEMBRANE ANTIGEN IMAGING FINDINGS AND SUBSEQUENT CLINICAL MANAGEMENT AMONG PATIENTS WITH BIOCHEMICAL RECURRENT PROSTATE CANCER: A RETROSPECTIVE COHORT STUDY
    Leapman, Michael S.
    Rabil, Maximilian
    Ghaffar, Umar
    Long, Jessica B.
    Westvold, Sarah
    Sprenkle, Preston
    Kim, Isaac Y.
    Saperstein, Lawrence
    Fallah, Jaleh
    Suzman, Daniel
    Lerro, Catherine
    Xu, Jianjin
    Kluetz, Paul G.
    Kunst, Natalia
    Wang, Shi-Yi
    Ma, Xiaomei
    Gross, Cary P.
    Karnes, R. Jeffrey
    JOURNAL OF UROLOGY, 2024, 211 (05): : E971 - E972
  • [32] Rates of clinically significant prostate cancer in African Americans increased significantly following the 2012 US Preventative Services Task Force recommendation against prostate specific antigen screening: A Single Institution Retrospective Study
    Arace, Jeffrey
    Flores, Viktor
    Monaghan, Thomas
    Robins, Dennis
    Karanikolas, Nicholas
    Winer, Andrew
    Weiss, Jeffrey
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2020, 74 (02)
  • [33] Comparison of prostate-specific antigen response in patients with metastatic castration-sensitive prostate cancer initiated on apalutamide or abiraterone acetate: A retrospective cohort study
    Lowentritt, Benjamin
    Pilon, Dominic
    Waters, Dexter
    Rossi, Carmine
    Muser, Erik
    Kurteva, Siyana
    Shah, Aditi
    Khilfeh, Ibrahim
    Du, Shawn
    Ellis, Lorie
    Lefebvre, Patrick
    Brown, Gordon
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2023, 41 (05) : 252.e19 - 252.e27
  • [34] Prostate-specific antigen bounce after curative brachytherapy for early-stage prostate cancer: A study of 274 African-Caribbean patients
    Leduc, N.
    Atallah, V.
    Creoff, M.
    Rabia, N.
    Taouil, T.
    Escarmant, P.
    Vinh-Hung, V.
    BRACHYTHERAPY, 2015, 14 (06) : 826 - 833
  • [35] The Impact of Prostate-Specific Antigen Screening on Prostate Cancer Incidence and Mortality in China: 13-Year Prospective Population-Based Cohort Study
    Ruan, Xiaohao
    Zhang, Ning
    Wang, Dawei
    Huang, Jingyi
    Huang, Jinlun
    Huang, Da
    Chun, Tsun Tsun Stacia
    Ho, Brian Sze Ho
    Ng, Ada Tsui-Lin
    Tsu, James Hok-Leung
    Zhan, Yongle
    Na, Rong
    JMIR PUBLIC HEALTH AND SURVEILLANCE, 2024, 10
  • [36] INCREASED DETECTION RATES OF INTERMEDIATE AND HIGH-GRADE PROSTATE CANCER IN AFRICAN-AMERICAN MEN AFTER 2012 USPSTF RECOMMENDATION AGAINST PSA SCREENING
    Arace, Jeffrey
    Flores, Viktor
    Robins, Dennis
    Monaghan, Thomas
    Winer, Andrew
    Weiss, Jeffrey
    JOURNAL OF UROLOGY, 2019, 201 (04): : E650 - E650
  • [37] Prostate-Specific Antigen Screening Test: Is It Overused in Prostate Cancer Practice? Retrospective Study of the Data From Brooklyn VA Medical Center From 1997 to 2007
    Li, Weijie
    Wieczorek, Rosemarry L.
    Desoto-Lapix, Fidelina
    Blank, William
    Pincus, Matthew R.
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2010, 134 (04) : 678 - 678
  • [38] Factors Related to Prostate-Specific Antigen-Based Prostate Cancer Screening in Primary Care: Retrospective Cohort Study of 120,587 French Men Over the Age of 50 Years
    Rat, Cedric
    Schmeltz, Heloise
    Rocher, Sylvain
    Nanin, France
    Gaultier, Aurelie
    Nguyen, Jean-Michel
    JMIR PUBLIC HEALTH AND SURVEILLANCE, 2018, 4 (04): : 172 - 182
  • [39] There is a need of novel risk classifications in prostate cancer. An invited commentary on 'Reduced cancer-specific survival of low prostate-specific antigen in high-grade prostate cancer: A population-based retrospective cohort study'
    Gomez Rivas, Juan
    Enikeev, Dmitry
    INTERNATIONAL JOURNAL OF SURGERY, 2020, 77 : 61 - 62
  • [40] Sensitivity of fluorine-18-fluoromethylcholine PET/CT to prostate-specific antigen over different plasma levels: a retrospective study in a cohort of 192 patients with prostate cancer
    Giovacchini, Giampiero
    Giovannini, Elisabetta
    Borso, Elisa
    Lazzeri, Patrizia
    Riondato, Mattia
    Leoncini, Rossella
    Duce, Valerio
    Conti, Enrico
    Picchio, Maria
    Ciarmiello, Andrea
    NUCLEAR MEDICINE COMMUNICATIONS, 2019, 40 (03) : 258 - 263